top of page

Leadership

Patty Limphong_Director, Bioanalytical.jpg

Patty Limphong, Ph.D.
Founder and CEO

Patty Limphong is the Chief Executive Officer and Founder of SoCal Biosciences. With over 15 years of experience, Dr. Limphong has an exceptional background and technical foundation in oligonucleotides, large molecules, small molecules, cell-based assays, and analytical/bioanalytical assay development. Prior to SoCal Biosciences, Dr. Limphong was a Director at Arcturus Therapeutics where she co-developed and established the mRNA and siRNA platform, resulting in over 6 patents granted and pending. At Arcturus, Dr. Limphong formed and grew two well-recognized departments: mRNA Production and Process Development team and a Bioanalytical team where she led the development of several analytical and bioanalytical assays to support pipeline growth and progression. Dr. Limphong also has expertise in stem cell and cell biology. She had the opportunity to learn stem cell and iPSC techniques at the Gladstone Institute, UCSF under Dr. Deepak Srivastava and Dr. Shinya Yamanaka. She used her knowledge and expertise to build the stem cell core facility at the University of Utah Hospital and at the John Hopkins Hospital where she supported scientific research and trained scientists, post-doctoral researchers, and students. Dr. Limphong is highly experienced with assay development, method qualification, and method transfer, and leading the execution of assays at CMOs and CROs for non-clinical and clinical studies; accountable for over 20 non-clinical and clinical studies. She has authored and prepared numerous bioanalytical and pharmacokinetic (PK) sections of regulatory submissions (i.e., IND, CTA, IB, jNDA) to enable clinical trials for vaccines and therapeutic programs. She is the author of over 20 peer review publications and books and serves as a consultant for several companies in the biotech industry. Patty Limphong earned her Ph.D. in Chemistry and Biochemistry from Miami University, Oxford, OH.

IMG_1584.heic

Trang Le
Director, Bioanalytical Development

Trang Le joined SoCal Biosciences in 2023 as the Director of Bioanalytical Development, bringing over two decades of experience in GLP large molecule bioanalytical services.  Prior to that, she has made recognizable contributions to leading companies including Bristol-Myers Squibb, Scripps Immunology Reference Laboratory, Intertek Pharmaceuticals Services, MicroConstants and BioAgilytix. Trang’s group conducts method development, validation, and implementation of bioanalytical projects for drug pharmacokinetic and immunogenicity assessments, as well as biomarker and cell-based sample analyses. Methods include predominantly ligand-binding immunoassays and enzymatic assays.  Her expertise extends to FDA and client audits, and her client base ranges from startups to large pharmaceutical firms. Trang's work is built upon a foundation of exceptional results and positive relationships with study sponsors. Trang holds a BS degree in Biochemistry and Cell Biology from the University of California, San Diego.

Advisors

190603_BIOPhilly_Sriram Devanathan_Tue_11-04 AM_edited.jpg

Sriram Devanathan, Ph.D. , PMP
 

Dr. Devanathan obtained his doctoral degree in Chemistry and Biochemistry from Miami University of Ohio. He has pursued research on the discovery of novel biomarkers for metabolic disease, targeted drug development for oncological indications, and development of small molecule therapeutics for neurological diseases/disorders.

With his niche at the intersection of Scientific Research and Entrepreneurship, Dr. Devanathan has not only been involved in Strategic Planning and development of projects around discovering and developing therapeutics but also helping build those start-ups from the ground up both in operational capability as well as contributing to capital raising through NIH’s SBIR/STTR programs.  


Besides his professional accomplishment, Dr. Devanathan has been a champion for entrepreneurship and economic empowerment and volunteered his time and expertise to many causes, including The BALSA Group, Arch Grants, Mosaic Project, and Venture café, to name a few. He has also second in the boards of non-profit entities. Dr. Devanathan has been recognized in the past by the regional chamber, the Regional
business council, and the Business Journal.

bottom of page